# US 2024/0360593 A1 · Production method of innovative nanofiber medical textile material with transdermal- drug release properties

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0360593 A1
- Document ID: US20240360593A1
- Status: Published application
- Kind: A1
- Application number: 18/292,885
- Filed: 2022-11-15
- Published: 2024-10-31
- Earliest claimed: 2021-11-15
- Assignees: SüLeyman Demirel üNiversitesi Idari Ve Mali Isler Daire Baskanligi Genelsekreterlik
- Applicants: SüLeyman Demirel üNiversitesi Idari Ve Mali Isler Daire Baskanligi Genelsekreterlik
- Inventors: Funda CENGIZ ÇALLIOGLU; Hülya KESICI GÜLER
- Web page: https://patentgrep.com/patent/US20240360593A1

## CPC

- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- D01D 5/0007: {Electro-spinning (non-woven fabrics produced by electro-spinning D04H1/728)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- D01F 1/10: Other agents for modifying properties
- D01F 6/56: of polymers of cyclic compounds with one carbon-to-carbon double bond in the side chain
- D06M 13/372: containing etherified or esterified hydroxy groups {; Polyethers of low molecular weight}
- D06M 23/10: Processes in which the treating agent is dissolved or dispersed in organic solvents; Processes for the recovery of organic solvents thereof
- D06M 2101/18: Synthetic fibres consisting of macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D06M 2200/00: Functionality of the treatment composition and/or properties imparted to the textile material
- D10B 2211/20: Protein-derived artificial fibres
- D10B 2321/12: polymers of cyclic compounds with one carbon-to-carbon double bond in the side chain
- D10B 2509/00: Medical; Hygiene
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- D01D: MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01F: CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D06M: TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D10B: INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES

## Abstract

Disclosed herein is the production of medical textile material with nanofiber surface that has transdermal drug release properties and that is coated with azithromycin active substance by using needle electrospinning method and ultrasonic spray pyrolysis (USP) technique. Specifically disclosed is a nanofiber medical textile material production method that includes the steps of preparing polymer solutions containing PVP (polyvinylpyrrolidone) with a concentration of 12 wt % and GEL (gelatin) with a concentration of 0.72 wt %; determining solution properties such as conductivity, viscosity, and surface tension, producing nanofibers from prepared polymer solutions by atmosphere-controlled horizontal needle fiber spinning (electrospinning) setup, obtaining PVP/GEL nanofibers after the fiber spinning process, thin film coating of the drug active substance on the obtained nanofibers, PVP/GEL nanofibers by the USP method, and cross-linking of both polymers to facilitate the final application processes of the drug-release material.

## Claims

### Claim 1

A production method of drug-loaded, PVP/GEL-based, nanofiber medical textile surfaces that can provide transdermal drug delivery as burst or controlled release, the method comprising:
a) preparing polymer solutions containing PVP (polyvinylpyrrolidone) with a concentration of 12 wt % and GEL (gelatin) with a concentration of 0.72 wt %,
b) producing nanofibers from prepared polymer solutions with atmosphere-controlled horizontal needle fiber spinning (electrospinning) set up,
c) performing cross-linking process in two steps to maintain the stability of the produced material in aqueous environments since both polymers are water soluble,
d) obtaining PVP/GEL nanofibers,
e) coating the drug active substance as a thin film on the obtained PVP/GEL nanofibers by the USP (ultrasonic spray pyrolysis) method.

### Claim 2 (depends on 1)

The production method according to claim 1, wherein the producing nanofibers further comprises: fiber spinning at 26.4 kV voltage, 0.3 mL/h feed rate, with a distance of 17.0 cm between the electrodes, and a needle diameter of 0.8 m, 33±2% humidity, and at 23.5±1° C. temperature for 60 minutes.

### Claim 3 (depends on 1)

The production method according to claim 1, wherein the coating the drug active substance further comprises: coating under a substrate temperature of 100° C., a flow rate of 1 mL/min, a nozzle frequency of 85 kHz, a distance between the nozzle and the substrate of 13 cm, and a forming nitrogen gas pressure of 1 kPA.

### Claim 4 (depends on 1)

The production method according to claim 1, wherein the performing the cross-linking further comprises:
first crosslinking PVP polymer at 180° C. for 4 hours,
then chemically cross-linking the GEL polymer with the glutaraldehyde crosslinker.

### Claim 5 (depends on 1)

The production method according to claim 1, wherein the coating the drug active substance further comprises:
providing a slow-release system by:
dissolving the drug active substance of the drug (Azithromycin) in chloroform first,
adding n-hexane as an anti-solvent to prevent the chloroform from dissolving the nanofiber surface,
adjusting the chloroform: n-hexane ratio in solution to 1:5,
adjusting the concentration of the drug active substance (Azithromycin) to 0.3 mg/mL.

### Claim 6 (depends on 5)

The production method according to claim 5, wherein an amount of AZI/chloroform/n-hexane solution coated is between 942 and 8460 μL.

### Claim 7 (depends on 1)

The production method according to claim 1, wherein a diameter of nano meshes coated with USP is 51-52 mm, a thickness of the nano meshes is 332.3-374.3 μm, and a weight of the nano meshes is 45.2-43.5 mg.

### Claim 8 (depends on 2)

The production method according to claim claim 2, further comprising:
providing a slow release system by:
coating the PVP/GEL nanofibers produced for 1 hour by USP to contain 0.7% AZI, and
producing PVP/GEL nanofibers in a sandwich structure on the coated surfaces for 5 to 60 minutes more.

### Claim 9 (depends on 1)

The production method according to claim 1, wherein a diameter of nano meshes coated with USP is 51-52 mm, a thickness of the nano meshes is 311.2-719.8 μm, and a weight of the nano meshes is 45.2-43.5 mg.
